JamesSunMD
General Surgery • Philadelphia, PASurgical Oncology (Other than Breast)
General Surgery Resident
Dr. Sun is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
Philadelphia, PA 19111Phone+1 215-854-9799
Summary
- CGSO Fellow at Fox Chase Cancer Center. Clinical and translational research interest in melanoma and breast cancer.
Education & Training
Temple University Hospital/Fox Chase Cancer CenterFellowship, Complex General Surgical Oncology, 2023 - 2025
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Surgery, 2020 - 2023
University of South Florida MorsaniFellowship, Complex General Surgical Oncology, 2018 - 2020
SUNY Downstate Health Sciences UniversityResidency, Surgery, 2016 - 2018
State University of New York Downstate Medical Center College of MedicineClass of 2016
Certifications & Licensure
FL State Medical License 2018 - 2022
Publications & Presentations
PubMed
- First-line Immunotherapy for Metastatic Merkel Cell Carcinoma: Analysis of Real-world Survival Data and Practice Patterns.Hanna Kakish, James Sun, John B Ammori, Richard S Hoehn, Luke D Rothermel
American Journal of Clinical Oncology. 2024-08-01 - 4 citationsThe Use of Gene Expression Profiling and Biomarkers in Melanoma Diagnosis and Predicting Recurrence: Implications for Surveillance and Treatment.James Sun, Kameko M Karasaki, Jeffrey M Farma
Cancers. 2024-01-30 - 1 citationsGrade of Primary Cutaneous Leiomyosarcoma Dictates Risk for Metastatic Spread and Disease-Specific Mortality.Michael J Carr, James Sun, William A Adams, Michelle M Dugan, Syeda M H Naqvi
Cancer Control. 2023-10-25
Press Mentions
Injecting Genetically Modified Virus into Tumor May Treat Metastatic MelanomaJanuary 31st, 2019
SMR 2019: Neoadjuvant T-VEC Improves 2-Year Recurrence-Free and Overall Survival in Resectable Stage 3B-4M1a MelanomaJune 25th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
